Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Catalina-2: A Phase 2 Study Evaluating the Efficacy and Safety of TORL-1-23 in Women With Advanced Platinum-Resistant Epithelial Ovarian Cancer (Including Primary Peritoneal and Fallopian Tube Cancers) Expressing Claudin 6

NCT06690775 is registered in ClinicalTrials.gov with TORL Biotherapeutics, LLC as lead sponsor.

NCT NCT06690775
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06690775 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Catalina-2: A Phase 2 Study Evaluating the Efficacy and Safety of TORL-1-23 in Women With Advanced Platinum-Resistant Epithelial Ovarian Cancer (Including Primary Peritoneal and Fallopian Tube Cancers) Expressing Claudin 6
Lead sponsor
TORL Biotherapeutics, LLC
Phase
Phase 2
Overall status
Recruiting
Start date
November 20, 2024
Completion date
December 31, 2027
Enrollment
230 (estimated)
Sites
66

Conditions

As the registry lists them; a condition with its own page is linked.

endometrioid ovarian cancer, epithelial ovarian cancer, fallopian tube cancer, primary peritoneal